The arrival of a new treatment class: First CELMoD approved for patients with multiple myeloma
The FDA has granted accelerated approval to our multiple myeloma treatment, bringing the first CELMoD-based regimen to patients as early as first relapse.
Learn more
AS OF JULY 30, 2026
- 49 Compounds in development
- 40+ Disease areas being studied
Our pipeline targets areas where we can deliver transformative medicines — for patients who need them most.